A phase II study of aprepitant, palonosetron, dexamethasone and olanzapine for the prevention of cisplatin-based hemotherapy-induced nausea and vomiting for thoracic malignancy

Trial Profile

A phase II study of aprepitant, palonosetron, dexamethasone and olanzapine for the prevention of cisplatin-based hemotherapy-induced nausea and vomiting for thoracic malignancy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2015

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone (Primary) ; Olanzapine (Primary) ; Palonosetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 14 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top